Oporia Osteoporosis NDA Review Extended To September
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's review of Pfizer's selective estrogen receptor modulator Oporia (lasofoxifene) for the treatment of osteoporosis has been extended until September
You may also be interested in...
Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.
US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: